Physician profile
Candace T Smith
NPI 1619908951
$1,307.53
in general payments reported to CMS, 2019-2025
21 companies · $47.88 in 2025
The $47.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $264 · 2021: $53.84 · 2023: $119 · 2024: $144 · 2025: $47.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $222.54 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $157.02 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Abbott Laboratories | $102.16 | 2019-2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $94.90 | 2020 | |
| Glaxosmithkline, LLC. | $88.75 | 2019-2023 | Arexvy, Shingrix |
| Amgen INC. | $71.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.00 | 2019 | |
| Pfizer INC. | $55.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $53.84 | 2021 | |
| Antares Pharma, INC. | $49.57 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.78 | 2019 | |
| Merck Sharp & Dohme LLC | $37.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.23 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.06 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.84 | 2020 | |
| Amarin Pharma, INC. | $14.98 | 2020 | |
| Eisai INC. | $14.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.94 | 2019 | |
| Astellas Pharma US INC | $12.69 | 2020 | |
| Ironshore Pharmaceuticals INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.